Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 167 participants.

Also called NCT01699932

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 167 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01699932
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Lebanon, Russia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01699932. Non-randomized; no masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled
Acronym
LEGEND
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Glimepiride+metformin (Amaryl M®) - HOE4900
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01699932
Content hash
44cc19a427e8f591557d122c47277db225454ed7698e84f8355382595875c14e